The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update
Open accessAbstract
Proton pump inhibitors (PPIs) are used extensively for the treatment of gastric acid-related disorders, often over the long term, which raises the potential for clinically significant drug interactions in patients receiving concomitant medications. These drug-drug interactions have been previously reviewed. However, the current knowledge is likely to have advanced, so a thorough review of the literature published since 2006 was conducted. This identified new studies of drug interactions that are modulated by gastric pH. These studies showed the effect of a PPI-induced increase in intragastric pH on mycophenolate mofetil pharmacokinetics, which were characterised by a decrease in the maximum exposure and availability of mycophenolic acid, at least at early time points. Post-2006 data were also available outlining the altered pharmacokinetics of protease inhibitors with concomitant PPI exposure. New data for the more recently marketed dexlansoprazole suggest it has no impact on the pharmacokinetics of diazepam, phenytoin, theophylline and warfarin. The CYP2C19-mediated interaction that seems to exist between clopidogrel and omeprazole or esomeprazole has been shown to be clinically important in research published since the 2006 review; this effect is not seen as a class effect of PPIs. Finally, data suggest that coadministration of PPIs with methotrexate may affect methotrexate pharmacokinetics, although the mechanism of interaction is not well understood. As was shown in the previous review, individual PPIs differ in their propensities to interact with other drugs and the extent to which their interaction profiles have been defined. The interaction profiles of omeprazole and pantoprazole sodium (pantoprazole-Na) have been studied most extensively. Several studies have shown that omeprazole carries a considerable potential for drug interactions because of its high affinity for CYP2C19 and moderate affinity for CYP3A4. In contrast, pantoprazole-Na appears to have lower potential for interactions with other medications. Lansoprazole and rabeprazole also seem to have a weaker potential for interactions than omeprazole, although their interaction profiles, along with those of esomeprazole and dexlansoprazole, have been less extensively investigated. Only a few drug interactions involving PPIs are of clinical significance. Nonetheless, the potential for drug interactions should be considered when choosing a PPI to manage gastric acid-related disorders. This is particularly relevant for elderly patients taking multiple medications, or for those receiving a concomitant medication with a narrow therapeutic index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
Ho, P. M. (2009) · JAMA · doi:10.1001/jama.2009.261 · Cited by 1,007
Chiba, N., De Gara, C., Wilkinson, J., & Hunt, R. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9178669 · Cited by 857
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., Tu, J. V., Henry, D. A., Kopp, A., & Mamdani, M. M. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.082001 · Cited by 766
Li, X.-Q., Andersson, T. B., Ahlström, M., & Weidolf, L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.821 · Cited by 644
Adverse Drug Events In High Risk Older Outpatients
Hanlon, J. T., Schmader, K. E., Koronkowski, M. J., Weinberger, M., Landsman, P. B., Samsa, G. P., & Lewis, I. K. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb02964.x · Cited by 443
Small, D. S., Farid, N. A., Payne, C. D., Weerakkody, G. J., Li, Y. G., Brandt, J. T., Salazar, D. E., & Winters, K. J. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008315310 · Cited by 316
A guideline for the treatment and prevention of NSAID-induced ulcers
Lanza, F. L. (1998) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00588.x · Cited by 276
Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole
Andersson, T., Hassan-Alin, M., Hasselgren, G., R??hss, K., & Weidolf, L. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140060-00003 · Cited by 239
A guideline for the treatment and prevention of nsaid-induced ulcers
Lanza, F. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00469-9 · Cited by 239
Bates, E. R., Lau, W. C., & Angiolillo, D. J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.024 · Cited by 231
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein
Pauli-Magnus, C., Rekersbrink, S., Klotz, U., & Fromm, M. F. (2001) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-001-0489-7 · Cited by 230
Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors
Blume, H., Donath, F., Warnke, A., & Schug, B. S. (2006) · Drug Safety · doi:10.2165/00002018-200629090-00002 · Cited by 216
Self-citationDrug-Drug Interaction Profiles of Proton Pump Inhibitors
Ogawa, R., & Echizen, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531320-000000000-00000 · Cited by 179
KWOK, C. S., & LOKE, Y. K. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04247.x · Cited by 178
Pharmacogenetics and herb???drug interactions: experience with Ginkgo biloba and omeprazole
Yin, O. Q., Tomlinson, B., Waye, M. M., Chow, A. H., & Chow, M. S. (2004) · Pharmacogenetics · doi:10.1097/00008571-200412000-00007 · Cited by 178
Andersson, T., Cederberg, C., Edvardsson, G., Heggelund, A., & Lundborg, P. (1990) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1990.12 · Cited by 165
Gugler, R., & Jensen, J. C. (1985) · PubMed · Cited by 164
Cheer, S. M., Prakash, A., Faulds, D., & Lamb, H. M. (2003) · Drugs · doi:10.2165/00003495-200363010-00006 · Cited by 161
Omeprazole inhibits oxidative drug metabolism
Gugler, R., & Jensen, J. C. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90638-9 · Cited by 158
Frelinger, A. L., Lee, R. D., Mulford, D. J., Wu, J., Nudurupati, S. V., Nigam, A., Brooks, J. K., Bhatt, D. L., & Michelson, A. D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.024 · Cited by 151
Welage, L. S., & Berardi, R. R. (2000) · Journal of the American Pharmaceutical Association (1996) · doi:10.1016/s1086-5802(16)31036-1 · Cited by 149
Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole
Chin, T. W., Loeb, M. B., & Fong, I. W. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1671 · Cited by 149
Wang, L., Zhou, G., Zhu, B. Y., Wu, J., Wang, J., El‐Aty, A. M. A., Li, T., Liu, J., Tian-lun, Y., Wang, D., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.014 · Cited by 145
Effect of omeprazole on the pharmacokinetics of itraconazole
Jaruratanasirikul, S., & Sriwiriyajan, S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050438 · Cited by 135
Andersson, T., Holmberg, J., Rohss, K. M., & Walan, A. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.t01-1-00702.x · Cited by 125
Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men
Sutfin, T. A., Balmér, K. C., Boström, H., Eriksson, S. A., Höglund, P., & Paulsen, O. (1989) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198903000-00010 · Cited by 124
Furuta, T., Ohashi, K., Kobayashi, K., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70034-2 · Cited by 121
Serum Iron, Ferritin, and Vitamin B12 During Prolonged Omeprazole Therapy
Koop, H., & Bachem, M. G. (1992) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199206000-00005 · Cited by 119
Drug Interaction Studies with Esomeprazole, the (S)-Isomer of Omeprazole
Andersson, T., Hassan‐Alin, M., Hasselgren, G., & hss, K. R. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00004 · Cited by 108
Rost, K. L., & Roots, I. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.49 · Cited by 104
Recent Safety Concerns With Proton Pump Inhibitors
Chen, J. W., Yuan, Y., Leontiadis, G. I., & Howden, C. W. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182333820 · Cited by 102
Clinical Pharmacokinetics of Lansoprazole
Landes, B. D., Petite, J. P., & Flouvat, B. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528060-00004 · Cited by 96
Oral phenytoin pharmacokinetics during omeprazole therapy.
Prichard, P., Walt, R. P., Kitchingman, G., et al. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03209.x · Cited by 93
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes
Yasui‐Furukori, N., Takahata, T., Nakagami, T., Yoshiya, G., Inoue, Y., Kaneko, S., & Tateishi, T. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02047.x · Cited by 90
Tomilo, D. L., Smith, P. F., Ogundele, A., DiFrancesco, R., Berenson, C. S., Eberhardt, E., Bednarczyk, E. M., & Morse, G. D. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.341 · Cited by 89
Yu, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114231 · Cited by 87
Effects of Omeprazole on Plasma Levels of Raltegravir
Iwamoto, M., Wenning, L. A., Nguyen, B., Teppler, H., Moreau, A. R., Rhodes, R. R., Hanley, W. D., Jin, B., Harvey, C. M., Breidinger, S., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596503 · Cited by 87
Böttiger, Y., Tybring, G., Götharson, E., & Bertilsson, L. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90116-8 · Cited by 84
Ishizaki, T., Chiba, K., Manabe, K., Koyama, E., Hayashi, M., Yasuda, S., Horai, Y., Tomono, Y., Yamato, C., & Toyoki, T. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90193-0 · Cited by 81
A study of the interaction of omeprazole and warfarin in anticoagulated patients.
Unge, P., Svedberg, L., Nordgren, A., et al. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb05656.x · Cited by 79
Funck‐Brentano, C., Becquemont, L., Leneveu, A., Roux, A., Jaillon, P., & Beaune, P. H. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36460-2 · Cited by 77
Oosterhuis, B., Jonkman, J. H. G., Andersson, T., Zuiderwijk, P., & Jedema, J. N. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb03953.x · Cited by 68
Soons, P. A., van den Berg, G., Danhof, M., van Brummelen, P., Jansen, J. B. �. �., Lamers, C. B. H. W., & Breimer, D. D. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf00266355 · Cited by 66
Influence of lansoprazole treatment on diazepam plasma concentrations
Lefebvre, R. A., Flouvat, B., Karolac-Tamisier, S., et al. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.172 · Cited by 64
Rupprecht, K., Schmidt, C., Raspé, A., Schweda, F., Shipkova, M., Fischer, W. H., Bucher, M., Kees, F., & Faerber, L. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009344988 · Cited by 64
Singh, G., & Triadafilopoulos, G. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00660.x · Cited by 63
Palovaara, S., Tybring, G., & Laine, K. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01868.x · Cited by 61
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses
Gremse, D. A. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.10.1663 · Cited by 54
Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline
Dilger, K., Zheng, Z., & Klotz, U. E. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00043.x · Cited by 46
Lack of pharmacokinetic interaction of pantoprazole with diazepam in man
Gugler, R., HARTMANN, M., RUDI, J., et al. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.40619.x · Cited by 46
Absorption Kinetics of Levothyroxine Is Not Altered by Proton-pump Inhibitor Therapy
Dietrich, J. W., Gieselbrecht, K., Holl, R. W., & Boehm, B. O. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-924980 · Cited by 44
A Study of the Interaction Between Omeprazole and Phenytoin in Epileptic Patients
Andersson, T., Lagerström, P.-O., & Unge, P. (1990) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199007000-00005 · Cited by 43
Calabresi, L., Pazzucconi, F., Ferrara, S., Paolo, A. D., Tacca, M. D., & Sirtori, C. R. (2003) · Pharmacological Research · doi:10.1016/j.phrs.2003.10.010 · Cited by 41
Duursema, L., Muller, F., Schall, R., Middle, M. V., Hk, H., Groenewoud, G., Steinijans, V., & Bliesath, H. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05732.x · Cited by 39
Fang, A. F., Damle, B. D., LaBadie, R. R., Crownover, P. H., Hewlett, D., & Glue, P. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.1.42 · Cited by 38
The Role of Cytochrome P2C19 in R-warfarin Pharmacokinetics and its Interaction With Omeprazole
Uno, T., Sugimoto, K., Sugawara, K., & Tateishi, T. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31816e2d8e · Cited by 37
Quinn, D. I., Nemunaitis, J. J., Fuloria, J., Britten, C. D., Gabrail, N. Y., Yee, L., Acharya, M. R., Chan, K., Cohen, N., & Dudov, A. (2009) · Clinical Pharmacokinetics · doi:10.2165/00003088-200948030-00006 · Cited by 37
A study of the interaction between omeprazole and cyclosporine in renal transplant patients.
Blohmé, I., Idström, J., & Andersson, T. (1993) · PubMed · Cited by 35
Portolés, A., Calvo, A., Terleira, A. I., et al. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291624 · Cited by 33
The potential interaction between clopidogrel and proton pump inhibitors: a systematic review
Aquino, J. P. D., & Brophy, J. M. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-81 · Cited by 31
Vakily, M., Lee, R. D., Wu, J., Gunawardhana, L., & Mulford, D. J. (2008) · Clinical Drug Investigation · doi:10.2165/0044011-200929010-00004 · Cited by 31
Kofler, S., Wolf, C., Shvets, N., Sisic, Z., Müller, T., Behr, J., Sohn, H., Vogeser, M., Shipkova, M., Meiser, B., et al. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.12.003 · Cited by 30
Andersson, T., Bredberg, E., Lagerström, P. O., Næsdal, J., & Wilson, I. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050482 · Cited by 29
Effect of Omeprazole on the Pharmacokinetics of Oral Gemifloxacin in Healthy Volunteers
Allen, A., Vousden, M., & Lewis, A. (1999) · Chemotherapy · doi:10.1159/000007244 · Cited by 24
Theophylline steady state pharmacokinetics is not altered by omeprazole
Taburet, A. M., Genève, J., Bocquentin, M., et al. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf00266361 · Cited by 17
Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin
Washington, C. B., Hou, E., Hughes, N., et al. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050355 · Cited by 15
Lansoprazole and Ethanol Metabolism: Comparison with Omeprazole and Cimetidine
Battiston, L., Tulissi, P., Moretti, M., & Pozzato, G. (1997) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1997.tb00001.x · Cited by 10
Lack of Interaction between Pantoprazole and Ethanol
Heinze, H., Fischer, R., tzer, R. H. P., Teyssen, S., & Singer, M. V. (2001) · Clinical Drug Investigation · doi:10.2165/00044011-200121050-00004 · Cited by 5
Cited by
for the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469
Addressing phenoconversion: the Achilles' heel of personalized medicine
Shah, R. R., & Smith, R. L. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12441 · Cited by 278
Metadata
- Authors
- Wedemeyer, R.-S., & Blume, H.
- Venue
- Drug Safety
- Published
- 2014-02-19
- Volume
- 37
- Issue
- 4
- Pages
- 201-211
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W2110602156
- Cited by
- 310
- References
- 70
- FWCI
- 29.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.